Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients

BACKGROUND: Roxadustat is a newly listed oral hypoxia-inducible factor-proline enhancing enzyme inhibitor (HIF-PHI) in recent years. There have been some studies that have proved the efficacy of roxadustat on the treatment of renal anemia in patients with chronic kidney disease (CKD), but there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Juanjuan, Li, Han, Wang, Shixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678462/
https://www.ncbi.nlm.nih.gov/pubmed/36420092
http://dx.doi.org/10.1155/2022/2413176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678462/
https://www.ncbi.nlm.nih.gov/pubmed/36420092
http://dx.doi.org/10.1155/2022/2413176

Ejemplares similares